TY - JOUR
T1 - Unexpected suppression of tumorigenesis by c-MYC via TFAP4-dependent restriction of stemness in B lymphocytes
AU - Tonc, Elena
AU - Takeuchi, Yoshiko
AU - Chou, Chun
AU - Xia, Yu
AU - Holmgren, Melanie
AU - Fujii, Chika
AU - Raju, Saravanan
AU - Chang, Gue Su
AU - Iwamoto, Masahiro
AU - Egawa, Takeshi
N1 - Funding Information:
This work was supported by National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases grants R56 AI114593-01A1 (T.E.) and R01 AI130152-01A1 (T.E.), and NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) grant R01 AR046000 (M.I.); Leukemia and Lymphoma Society Scholar Award 1349-18 (T.E.); a Siteman Investment Program Research Development Award (T.E.); and a Hu and Zeng Predoctoral Scholarship (E.T.). The Washington University Rheumatic Diseases Research Resource-based Center is supported by NIH, NIAMS grant P30 AR073752. The Genome Technology Access Center is supported, in part, by NIH, National Cancer Institute Cancer Center Support Grant P30CA91842 to the Siteman Cancer Center, and by the Institute of Clinical and Translational Sciences/Clinical and Translational Science Award (UL1TR000448) from the National Center for Research Resources, a component of the NIH, and the NIH Roadmap for Medical Research.
Publisher Copyright:
© 2021 American Society of Hematology
PY - 2021/12/16
Y1 - 2021/12/16
N2 - The proliferative burst of B lymphocytes is essential for antigen receptor repertoire diversification during the development and selective expansion of antigen-specific clones during immune responses. High proliferative activity inevitably promotes oncogenesis, the risk of which is further elevated in B lymphocytes by endogenous gene rearrangement and somatic mutations. However, B-cell–derived cancers are rare, perhaps owing to putative intrinsic tumor-suppressive mechanisms. We show that c-MYC facilitates B-cell proliferation as a protumorigenic driver and unexpectedly coengages counteracting tumor suppression through its downstream factor TFAP4. TFAP4 is mutated in human lymphoid malignancies, particularly in >10% of Burkitt lymphomas, and reduced TFAP4 expression was associated with poor survival of patients with MYC-high B-cell acute lymphoblastic leukemia. In mice, insufficient TFAP4 expression accelerated c-MYC–driven transformation of B cells. Mechanistically, c-MYC suppresses the stemness of developing B cells by inducing TFAP4 and restricting self-renewal of proliferating B cells. Thus, the pursuant transcription factor cascade functions as a tumor suppressor module that safeguards against the transformation of developing B cells.
AB - The proliferative burst of B lymphocytes is essential for antigen receptor repertoire diversification during the development and selective expansion of antigen-specific clones during immune responses. High proliferative activity inevitably promotes oncogenesis, the risk of which is further elevated in B lymphocytes by endogenous gene rearrangement and somatic mutations. However, B-cell–derived cancers are rare, perhaps owing to putative intrinsic tumor-suppressive mechanisms. We show that c-MYC facilitates B-cell proliferation as a protumorigenic driver and unexpectedly coengages counteracting tumor suppression through its downstream factor TFAP4. TFAP4 is mutated in human lymphoid malignancies, particularly in >10% of Burkitt lymphomas, and reduced TFAP4 expression was associated with poor survival of patients with MYC-high B-cell acute lymphoblastic leukemia. In mice, insufficient TFAP4 expression accelerated c-MYC–driven transformation of B cells. Mechanistically, c-MYC suppresses the stemness of developing B cells by inducing TFAP4 and restricting self-renewal of proliferating B cells. Thus, the pursuant transcription factor cascade functions as a tumor suppressor module that safeguards against the transformation of developing B cells.
UR - http://www.scopus.com/inward/record.url?scp=85121100350&partnerID=8YFLogxK
U2 - 10.1182/blood.2021011711
DO - 10.1182/blood.2021011711
M3 - Article
C2 - 34283887
AN - SCOPUS:85121100350
SN - 0006-4971
VL - 138
SP - 2526
EP - 2538
JO - Blood
JF - Blood
IS - 24
ER -